Kontakt
GBG Forschungs GmbH
Martin-Behaim-Straße 12
63263 Neu-Isenburg
Tel.: +49610274800
Fax: +4961027480440
E-Mail: Infgbgd
Kontaktformular
News
-
17.08.2017 Effect of BRCA1/2 Status on Response to Neoadjuvant Carboplatin in TNBC
Our paper on mutations analysis in the Geparsixto TNBC-Arm was discussed at ASCO-News.
Mehr ... -
12.07.2017 Invitation MAP Onco Congress
A joint initiative of ESMO, UNICANCER and Cancer Research UK, this conference shines a light on the latest medical developments in a constantly evolving field. 13-14 Oct 2017 at Swissôtel Zurich.
Mehr ... -
05.07.2017 PALOMA-3 Results published
Palbociclib Combined with Fulvestrant in PremenopausalWomen with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results
Mehr ... -
03.02.2017 How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?
Prof. Loibl and Prof. Denkert discuss "How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?" in the current JCO Editorial.
Mehr ... -
GBG Jahrestreffen und AGO Mamma State of the Art
Vom 2. bis 3. März 2017 findet das GBG Jahrestreffen 2017 und am 4. März das AGO Mamma State of the Art-Meeting statt. Weitere Informationen finden Sie hier.
Mehr ... -
31.01.2017 Young Investigator Award
Die GBG vergibt einen Reise zum ESMO in Madrid in 2017 für junge Wissenschaftler. Bewerbung ab sofort möglich.
Mehr ... -
08.12.2016 The Lancet - Breast Cancer Series 2016
The introduction of targeted therapies has profoundly changed the course of some subtypes of breast cancer—but many challenges remain. The Lancet’s 2016 Series on breast cancer discusses the most recent advances in the three most common breast cancer subtypes. The first pair of papers focus on the treatment of advanced oestrogen-receptor-positive and HER2-positive breast cancers, while the third describes how an improved understanding of molecular alterations in the heterogeneous and hard-to-treat triple-negative breast cancer may lead to more refined and more effective therapy. http://www.thelancet.com/series/breast-cancer-2016
Mehr ... -
08.11.2016 Tailored, Dense-Dose Chemotherapy for Early Breast Cancer Does Not Result in Significant Improvement in Recurrence-Free Survival
Among women with high-risk early breast cancer, the use of tailored dose-dense chemotherapy compared with standard adjuvant chemotherapy did not result in a statistically significant improvement in breast cancer recurrence-free survival, and nonhematologic toxic effects were more frequent in the tailored dose-dense group, according to a study appearing in the November 8 issue of JAMA.
Mehr ... -
11.10.2016 Immunotherapy for breast cancer: what does the future hold - BIG Research in Focus now available for download
In this issue introduced by Fabrice André (Institut Gustave Roussy, Villejuif, France), leading researchers exchange their views about the potential role of immunotherapies in breast cancer and our current understanding of the immune response to this disease. In addition, an interview of Prof. Gabriel N. Hortobagyi (The University of Texas MD Anderson Cancer Center, USA) gives insight into the trans-Atlantic efforts aiming to move the field of immunotherapies forward faster. We hope you will enjoy the reading.
Mehr ... -
01.08.2016 GAIN 2 – Amendment 3 – neoadjuvanter Behandlungarm ist geöffnet
Am 01. August 2016 wurde Amendment 3 der Gain 2 Studie live geschaltet. Es beinhaltet die Öffnung für den neoadjuvanten Behandlungszweig. Zur Erreichung des Rekrutierungsziels (2.886 Patienten) wird die Studie bis QIV 2017 für den Einschluss von Patientinnen geöffnet bleiben.
Mehr ... -
28.07.2016 GBG Annual Meeting 2017 - Save the Date!
Vom 2. bis 3. März 2017 findet in Frankfurt a.M. das GBG Jahrestreffen 2017 statt. Im Anschluss daran findet am 4. März 2017 das AGO Mamma State of the Art Meeting statt. Weitere Informationen finden Sie in unserem Veranstaltungsbereich.
Mehr ... -
14.07.2016 PenelopeB – 50% Rekrutierungsziel erreicht
Am 07. Juli 2016 wurde die 550. Patientin am Krankenhaus Hietzing Wien / Prof. Dr. Sevelda in die PenelopeB Studie randomisiert. Damit wurden 50% der Gesamtrekrutierung erreicht.
Mehr ... -
30.06.2016 INSEMA – 1.000 patients
Mit Ihrer Hilfe wurde am 30. Juni 2016 die 1.000ste Patientin in die INSEMA-Studie eingeschlossen. Damit ist die geplante Rekrutierungszahl von 5.940 Patienten ein realistisches Ziel. Herzlichen Dank für diese großartige Leistung an alle teilnehmenden Zentren!
Mehr ... -
30.05.2016 Sponsorship award 2015 from the Fritz Acker Foundation
Prof. Dr. med. Sibylle Loibl has won the sponsorship award of the Fritz Acker Foundation in recognition of her research work in the field of oncology.
Mehr ... -
31.03.2016 Guidelines from the Breast Committee of the Working Group for Gynaecological Oncology (AGO)
The current guidelines from the AGO Breast Committee are published on the AGO’s website.
Mehr ... -
24.03.2016 Order coupon for Breast Care 2016
Courtesy of the publishing house Karger Verlag, we have again received an order coupon for the “Breast Care” journal 2016. This order coupon entitles GBG members to request a free sample issue or take out a subscription. The form can be downloaded here.
Mehr ... -
08.03.2016 Annual Meeting of the GBG 2016
With over 500 participants, the Annual Meeting was a resounding success. The presentations given on 3 and 4 March will be published in our event archive shortly. Please save the date of the GBG’s next annual meeting: 2 – 3 March 2017.
Mehr ... -
03.03.2016 Relaunch of the website
All good things take time: the new GBG website has been online since 3 March 2016. We would be pleased to receive your feedback on the new website via the contact form.
Mehr ...
GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440